Phase 3 Schizophrenia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are about to start, or who have started within the last 8 weeks, taking one of these antipsychotic medications for psychosis: olanzapine, quetiapine (at a full therapeutic dose, not a low dose used only as a sleep aid), clozapine, or risperidone
- People aged between 18 and 65 years old
- People who have not used any of these four antipsychotic medications for more than one week in a row during the past 6 months (not counting the current medication if it was started within the last 8 weeks)
- People who understand the study and are able to sign a written consent form
Who may not be able to join:
- People who are critically ill (for example, currently in an intensive care unit), or who have been diagnosed with an eating disorder, a long-term gut or digestive condition, a liver or pancreas disorder, diabetes, or metabolic syndrome
- People currently taking medications that affect metabolism or weight (such as diabetes medications or GLP-1 medications), proton pump inhibitors, diuretics, or beta blockers, or who have taken antibiotics or probiotic supplements (such as Yakult, Activia, or similar products containing large numbers of live bacteria) in the past 4 weeks
- People who are pregnant or breastfeeding
- People who, in the treating doctor's judgment, would be unable to follow the study requirements or have other conditions that might affect the study results (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Iris E.C. Sommer, Prof. Dr., University Medical Center Groningen
Phone: +31681528283
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Hemoglobin A1C
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.